Don't Jump to DOACs First-Line for Cancer-Related VTE
We're getting questions about whether to use a direct oral anticoagulant (DOAC) in patients with cancer-associated thromboembolism.
The role of DOACs (apixaban, rivaroxaban, etc) is expanding. Chest guidelines now favor these meds for most patients with venous thromboembolism (VTE)...deep vein thrombosis or pulmonary embolism.
But don't jump to a DOAC first-line to treat or prevent recurrent VTE in cancer patients...due to limited efficacy and safety data.